Steegen K, Luchters S, De Cabooter N, Reynaerts J, Mandaliya K, Plum J, Jaoko W, Verhofstede C, Temmerman M.Evaluation of two commercially available alternatives for HIV-1 viral load testing in resource-limited settings.J Virol Methods. 2007 Dec;146(1-2):

Citation:
W. PROFJAOKOGODFREY. "Steegen K, Luchters S, De Cabooter N, Reynaerts J, Mandaliya K, Plum J, Jaoko W, Verhofstede C, Temmerman M.Evaluation of two commercially available alternatives for HIV-1 viral load testing in resource-limited settings.J Virol Methods. 2007 Dec;146(1-2):.". In: J Virol Methods. 2007 Dec;146(1-2):178-87. Epub 2007 Aug 7. AIDS 24(6):891-7; 2007.

Abstract:

There is an urgent need for low-cost assays for HIV-1 quantitation to ensure adequate follow-up of HIV-infected patients on antiretroviral therapy (ART) in resource-limited countries. Two low-cost viral load assays are evaluated, a reverse transcriptase activity assay (ExavirLoad v2, Cavidi) and a real-time reverse transcriptase PCR assay (Generic HIV viral load, Biocentric). Both tests were compared with the ultrasensitive HIV Amplicor Monitor assay. Samples were collected in Mombasa, Kenya, from 20 HIV-1 seronegative and 150 HIV-1 seropositive individuals of whom 50 received antiretroviral treatment (ART). The ExavirLoad and the Generic HIV viral load assay were performed in a local laboratory in Mombasa, the Amplicor Monitor assay (version 1.5, Roche Diagnostics) was performed in Ghent, Belgium. ExavirLoad and Generic HIV viral load reached a sensitivity of 98.3% and 100% and a specificity of 80.0% and 90.0%, respectively. Linear regression analyses revealed good correlations between the Amplicor Monitor and the Generic HIV viral load (r=0.935, p<0.001) with high accuracy (100.1%), good precision (5.5%) and a low percent similarity coefficient of variation (5.4%). Bland-Altman analysis found 95% of the samples within clinically acceptable limits of agreement (-1.19 to 0.87logcopies/ml). Although, the ExavirLoad also showed a good linear correlation with the Amplicor Monitor (r=0.901, p<0.001), a problem with false positive results was more significant. The cost per test remains relatively high (US$ 30 for ExavirLoad and US$ 20 for the Generic HIV viral load). Hence, false positive results and the need for an expensive PCR instrument for the Generic HIV viral load assays still limit the implementation of these tests in less equipped, less experienced laboratories.

Notes:

n/a

Website

UoN Websites Search